The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

REMAIN-1 is now recruiting patients, Singh said, who have either have lost weight or will take Zepbound to lose 15% of their body weight. When the desired weight loss is achieved, they will ...

In Q4 2024, the company saw a 45% increase in revenue, reaching $13.53 billion, driven by strong volume growth from Mounjaro and Zepbound. Earnings per share (EPS) for the quarter doubled ...

People searched for Wegovy, Zepbound, and phentermine at rates ... which have been shown to help with weight loss. The link between prescriptions and online searches suggests that public awareness ...